Ladenburg Thalmann & Co. Inc.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million. Research and development expenses were $5.1 million for the first quarter of 2022, including stock-based compensation of $0.5 million. General and...